BioMarker Strategies awarded Phase II National Cancer Institute Contract to develop novel predictive test

The SnapPath cancer diagnostics system, developed and patented by BioMarker Strategies, is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. (Credit: Business Wire)

Related Article
Recommended Whitepaper

View More